- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05757141
Fase 1b-studie om de veiligheid, verdraagbaarheid en farmacokinetiek van ABBV-CLS-7262 te onderzoeken bij patiënten met verdwijnende witte stof
Een open-label fase 1b-onderzoek om de veiligheid, verdraagbaarheid en farmacokinetiek te evalueren na toediening van ABBV-CLS-7262 bij volwassen proefpersonen met de ziekte van Vanishing White Matter
Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease.
Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Call Center - English
- Telefoonnummer: 1-833-250-9660
- E-mail: vwminfo@mylocalstudy.com
Studie Locaties
-
-
Quebec
-
Montreal, Quebec, Canada, H3H2L9
- Werving
- McGill University Health Centre - Glen Site
-
-
-
-
North Holland
-
Amsterdam, North Holland, Nederland, 1081 HV
- Werving
- Amsterdam UMC, locatie VUmc /ID# 270955
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Werving
- Massachusetts General Hospital /ID# 270960
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- Children's Hospital of Philadelphia
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112-5339
- Werving
- University of Utah /ID# 255624
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Males and females ≥18 y of age (Cohort 1 and Cohort 1b - adults), ≥12 y and <18 y of age (Cohort 2 - adolescents), ≥6 y and <12 y of age (Cohort 3 - children), and ≥6 mos and <6 y of age (Cohort 4 - children [≥1 y and <6 y of age] and infants [≥6 mos and <1 y of age]) at the time of Screening.
-
Subject must have VWM disease defined as:
- A clinical diagnosis by a physician experienced in the assessment of VWM disease, AND
- A molecular diagnosis of VWM disease (Note: Subjects who can provide a verified laboratory report of previously performed VWM molecular diagnosis, including the specific mutation(s), will not be required to reconfirm diagnosis before Screening), AND
- A magnetic resonance imaging (MRI) presentation consistent with VWM disease, as assessed by a neuroradiologist or by a physician experienced in the assessment of VWM disease except for presymptomatic homozygous carriers of Cree leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (requires approval from Sponsor).
-
Subject must have a designated caregiver who is able to complete the respective caregiver ce ntered assessments. The caregiver must be consistently present at visits, including telehealth visits, to report on symptoms and comply with the protocol. The caregiver must be willing to provide informed consent.
-
Subject is willing and able to give informed consent. Where local regulations permit inclusion of participants deemed not able to provide informed consent, a legally authorized representative (LAR) must provide informed consent on the subject's behalf, and the subject must provide assent, in accordance with the local regulations, guidelines, and Institutional Review Board (IRB), or Independent Ethics Committee (IEC). If the subject becomes cognitively impaired (diminished capacities) during the study and is unable to provide informed consent, the subject should be discontinued from the study unless local regulations permit inclusion of participants deemed not able to provide informed consent. In such case, a LAR must provide informed consent on behalf of the subject and the subject must provide assent as per local regulations, guidelines, and IRB or IEC. Careful consideration will be given to ensure that cognitive impairment/diminished capacity does not limit the subject's right to withdraw from the study. The LAR and the caregiver can be the same person.
-
Subjects in Cohorts 1, 1b, 2, and 3 must meet criteria a and at least 1 of the other criteria listed below (b or c):
- Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease
- Motor criteria as defined below:
All age groups:
Inability to walk 10 or more steps with or without light support of 2 hands
- Cognitive criteria as defined below (Note: Subjects are not required to complete testing if they meet the motor criteria or if they are able to provide source documentation of prior cognitive testing performed by a qualified psychologist and meeting eligibility criteria obtained in the past 12 months):
Adults and adolescents ≥16 y of age must have:
A perceptual reasoning index <50 (Wechsler Adult Intelligence Scale, fourth edition [WAIS-IV])
Adolescents and children ≥6 y and <16 y of age must have:
A visuospatial reasoning index <50 (block design, visual puzzles, Wechsler Intelligence Scale for Children performance, fifth edition [WISC-V]) AND A fluid reasoning index <50 (matrix reasoning, figure weights, WISC-V). Note: At the Sponsor's discretion, pediatric subjects <16 y of age who are unable to complete the subtests for calculating BOTH indices of the WISC-V due to functional impairment (e.g., due to fine motor or visual impairment) may meet inclusion criteria by a score <50 on either the visuospatial reasoning index OR the fluid reasoning index of the WISC-V.
Pediatric subjects in Cohort 4 must meet both criteria a and b below, or criterion c:
Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease
Motor criteria as defined below:
More than minimal head control as demonstrated by:
While in prone position, the subject can lift his/her head and sustain the position for 10 seconds and bring his/her arms actively to weight bearing in that position Presymptomatic and homozygous for Cree Leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (sponsor must be notified and provide approval prior to screening and enrolling a patient that meets eligibility with only this criterion).
-
All male subjects who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male subjects must agree to not donate sperm during the study and until 30 days after the final dose of study drug.
-
All female subjects who are sexually active and of childbearing potential must agree to use an acceptable contraceptive method. Additionally, female subjects must agree to not donate eggs during the study and for 30 days after the final dose of study drug.
-
Canada-specific Cohort 5: Male and female infant subjects between 0 mos and <6 mos of age at the time of Screening.
-
Canada-specific Cohort 5: Subject body weight ≥5 kg at the time of the Baseline visit. The screening period can be extended by up to 30 days to ensure that this minimum weight is met at the Baseline visit.
-
Canada-specific Cohort 5: Homozygous carriers of Cree leukoencephalopathy (EIF2B5 R195H) or other mutation(s) with known imminent risk of significant clinical decline or death (the Sponsor must be notified and provide approval prior to screening and enrolling a patient that meets eligibility with only this criterion).
An MRI presentation consistent with VWM disease is not required for Cohort 5. Exclusion Criteria
- Pediatric subjects ≥6 mos and <6 y of age must not be on any form of respiratory support at the time of Screening.
- Subject who has any clinically significant electrocardiogram (ECG) abnormalities, including QT interval corrected for heart rate using Fridericia's correction formula (QTcF) of >450 msec for adult males, >470 msec for adult females, or >450 msec for adolescents ≥12 y and <18 y of age (Cohort 2) and children ≥6 y and <12 y of age (Cohort 3), or >414 msec for infants and children ≥0.5 y and <6 y of age (Cohort 4).
- Subject with current or history of abnormal screening laboratory or imaging results that, in the opinion of the Investigator, are indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic, and/or other major disease (other than VWM) that would preclude administration of FGT or safe participation in the study Abnormal adrenal function, defined as confirmed abnormal random cortisol or ACTH at Screening (see Section 7.2.8 for cortisol and ACTH thresholds) Participants may undergo repeat cortisol and ACTH testing once, in order to establish normal adrenal function. If repeat cortisol and/or ACTH testing is abnormal, at the Investigator's discretion, the participant may undergo cosyntropin stimulation testing to establish normal adrenal function to meet eligibility criteria.
- Subject who has suicidal ideation at the Screening Visit (V1). Prior medical history and/or Columbia-Suicide Severity Rating Scale (C-SSRS) may be used to inform the Investigator's decision.
- Changes in medication use for the management of VWM disease symptoms within the 4 weeks preceding Screening.
- Seizure disorder not considered adequately controlled by the Investigator within the 6 months preceding Screening.
- Subject who, in the opinion of the Investigator, is incapable of completing study-required visits and procedures to assess primary and secondary endpoints (e.g., due to severe comorbid conditions or severity of VWM disease).
- Subjects who are pregnant, breastfeeding, or providing breast milk. Note: Infant subjects are permitted to receive breast milk from a non-participant mother or caregiver (who is not receiving the study intervention).
- Canada-specific Cohort 5: Subjects between 0 mos and <6 mos of age must not be on any form of respiratory support at the time of Screening.
- Canada-specific Cohort 5: Subject who has any clinically significant ECG abnormalities, including QT interval corrected for heart rate using Fridericia's correction formula (QTcF) of >414 msec for infants between 0 mos and <6 mos of age
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Fosigotifator - Cohort 1
Cohort 1: VWM adults >= 18 years. |
Oral Use
Andere namen:
|
|
Experimenteel: Fosigotifator - Cohort 1b
Cohort 1b: VWM adults >= 18 years. |
Oral Use
Andere namen:
|
|
Experimenteel: Fosigotifator - Cohort 2
Cohort 2: VWM children>= 12 y and <18 years. |
Oral Use
Andere namen:
|
|
Experimenteel: Fosigotifator - Cohort 3
Cohort 3: VWM children >= 6 y and <12 years. |
Oral Use
Andere namen:
|
|
Experimenteel: Fosigotifator - Cohort 4
Cohort 4: VWM children >= 6 months and <6 years. |
Oral Use
Andere namen:
|
|
Experimenteel: Fosigotifator - Cohort 5 (Canada Only)
VWM Children >0 and <6 months |
Oral Use
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events
Tijdsspanne: Baseline up to Approximately Day 28
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 |
Baseline up to Approximately Day 28
|
|
Number of Participants with Change in Vital Signs
Tijdsspanne: Baseline up to Approximately Day 28
|
Number of Participants with Change in Vital Signs will be assessed. |
Baseline up to Approximately Day 28
|
|
Number of Participants with Change in ECG
Tijdsspanne: Baseline up to Approximately Day 28
|
Number of Participants with Change in ECG will be assessed. |
Baseline up to Approximately Day 28
|
|
Number of Participants with Change in Clinical Laboratory Tests
Tijdsspanne: Baseline up to Approximately Day 28
|
Number of participants with change in clinical laboratory tests will be assessed. |
Baseline up to Approximately Day 28
|
|
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Tijdsspanne: Baseline up to Approximately Day 28
|
The C-SSRS is a systematically administered instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior. |
Baseline up to Approximately Day 28
|
|
Plasma Concentration of Fosigotifator
Tijdsspanne: Baseline up to approximately Week 96
|
Maximum Plasma Concentration [Cmax] |
Baseline up to approximately Week 96
|
|
Time to Cmax (Tmax) of Fosigotifator
Tijdsspanne: Baseline up to approximately Week 96
|
Tmax of Fosigotifator |
Baseline up to approximately Week 96
|
|
Area Under the Plasma Concentration-Time Curve (AUC0-24h) of Fosigotifator
Tijdsspanne: Baseline up to approximately Week 96
|
AUC0-24h of Fosigotifator |
Baseline up to approximately Week 96
|
|
Trough Concentration (Ctrough) of Fosigotifator
Tijdsspanne: Baseline up to approximately Week 96
|
Ctrough of Fosigotifator |
Baseline up to approximately Week 96
|
|
Terminal Elimination Half-Life (t1/2) of Fosigotifator
Tijdsspanne: Baseline up to approximately Week 96
|
t1/2 of Fosigotifator |
Baseline up to approximately Week 96
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events
Tijdsspanne: Baseline up to Approximately Week 197
|
Number of patients with treatment-related adverse events as assessed by CTCAE v4.03 |
Baseline up to Approximately Week 197
|
|
Number of Participants with Change in Vital Signs
Tijdsspanne: Baseline up to approximately Week 197
|
Number of Participants with Change in Vital Signs will be assessed. |
Baseline up to approximately Week 197
|
|
Number of Participants with Change in ECG
Tijdsspanne: Baseline up to approximately Week 197
|
Number of Participants with Change in ECG will be assessed. |
Baseline up to approximately Week 197
|
|
Number of Participants with Change in Clinical Laboratory Tests
Tijdsspanne: Baseline up to approximately Week 197
|
Number of participants with change in clinical laboratory tests will be assessed. |
Baseline up to approximately Week 197
|
|
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Tijdsspanne: Baseline up to approximately Week 197
|
The C-SSRS is a systematically administered instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior. |
Baseline up to approximately Week 197
|
|
Number of Participants with Change in Magnetic Resonance Imaging (MRI)
Tijdsspanne: Baseline up to approximately Week 192
|
Change in Brain Magnetic Resonance Imaging (MRI) associated with adverse events. |
Baseline up to approximately Week 192
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- M23-523
- 2023-505704-30-00 (Andere identificatie: EU CT)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .